ProCE Banner Activity

CE / CME

Current and Emerging Concepts for Optimizing Outcomes in HR+/HER2- Breast Cancer: The Role of CDK4/6 Inhibitors

Expert Insights

Most women diagnosed with breast cancer have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) disease. The standard of care for managing advanced HR+/HER2- breast cancer relies upon CDK4/6 inhibitors plus endocrine therapy—a combination that prolongs survival compared with endocrine therapy alone. Although the 3 CDK4/6 inhibitors approved by the FDA (abemaciclib, palbociclib, and ribociclib) have demonstrated comparable efficacy in patients with advanced HR+/HER2- breast cancer, there are important differences in their safety profiles, dosing, and specific indications—including the recent approval of abemaciclib as adjuvant therapy for select patients with early-stage breast cancer. In this activity, Jeremy Force, DO, discusses the recommended use of CDK4/6 inhibitors in clinical practice along with strategies for monitoring and managing adverse events, promoting adherence, and educating patients.

Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits

Released: November 24, 2021

Expiration: November 23, 2022

No longer available for credit.
Begin Activity

Share

Faculty

Jeremy M. Force

Jeremy M. Force, DO

Assistant Professor
Department of Medicine
Division of Medical Oncology
Breast Oncology Program
Duke University
Durham, North Carolina

Acknowledgement

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

 

Provided by

ProCE Banner

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Formulate treatment plans for the appropriate use CDK4/6 inhibitors for HR+/HER2- breast cancer

  • Use recommended approaches to manage toxicities associated with CDK4/6 inhibitors

  • Implement recommendations to improve adherence to treatment with CDK4/6 inhibitors

Disclosure

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Dr Force: consulting fees: Exact Sciences, Guardant Health, Pfizer; consulting fees/contracted research: G1 Therapeutics.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

CME Info

Participants wishing to earn CE/CME credit must:

  1. Review the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the post-test and evaluation form

Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.

The estimated time to complete this activity is 1.00 hour.

Release date: November 24, 2021
Expiration date: November 23, 2022

Format

eNewsletter with interactive benchmarking and audio commentary

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Accreditation

PCE

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

NP Course Advisor: Cynthia L. Teeple, APRN, MSN, ONP, White Plains Hospital, White Plains, New York

Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until November 23, 2022. PAs should only claim credit commensurate with the extent of their participation.

PA Course Advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

Program Medium

This program has been made available online.